|
|
|
|
| The success of nucleic acid modalities and LNP delivery systems relies on robust and consistent processes to make and purify the drug substance and then formulate it to ensure successful delivery to the intended target. A range of analytical techniques is necessary to ensure product quality and patient safety. This whitepaper provides a detailed description of assays for sequence identification and LNP composition, two critical quality attributes of mRNA-LNP products. Learn more here. |
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | Over the past few weeks since the guidance was released, I’ve spent some time listening to industry conversations and reading the guidance and related articles. In the following series of articles, I’ll share a few general impressions and (slightly spicy) thoughts I’ve been mulling over in response to the draft guidance. |
|
|
|
|
|
| Comparing Real-Time And Digital PCR Technologies | Infographic | Thermo Fisher Scientific | Which PCR technologies are the most effective? Examine digital PCR (dPCR) and real-time or quantitative PCR (qPCR) to determine the best choice for your labs. |
|
|
| mRNA Product IVT Process Insights | Article | Cytiva | In vitro transcription (IVT) allows a researcher to tailor synthesis and introduce modifications to produce a transcript. Learn about IVT along with process challenges and strategies. |
|
|
| The Future Of mRNA: Four Key Focuses For Industry | Article | Roche CustomBiotech | Compared to traditional protein-based therapies, mRNA drugs exhibit unique pharmacokinetic profiles and can be rapidly developed, making overcoming their challenges critical for the industry. |
|
|
|
.png){kind=logo}
